1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
MEKICS Co., Ltd.

MEKICS Co., Ltd.

KKRX:058110
1,437.00
KRW
-4.00
(-0.28%)
69.68EPS
28.61P/E
30.38BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,309.47
1,215.28
714.94
775.57
786.99
1,159.68
5,231.75
3,156.62
1,828.47
846.43
733.62
728.96
889.38
Basic EPS, GAAP
-4.84
350.56
-161.01
-175.52
-244.18
-129.1
1,857.22
607
-170
-1,029
-656
-164
68.52
Free Cash Flow per Basic Share
-1,248.39
-525.09
-230.22
-119.03
-166.7
-113.55
-455.28
222.74
49.74
-522.72
-478.76
-165.35
-17.3
Dividend per Share
2.23
- -
0.01
- -
- -
- -
- -
64.41
82.71
30
- -
- -
- -
Book Value per Share
165.12
924.63
887.53
709.81
457.94
364.69
2,672.7
4,528.35
4,311.81
3,191.05
2,528.18
2,364.55
2,407.71
Tangible Book Value per Share
163.24
914.88
876.01
698.78
387.22
295.1
2,620.49
4,403.18
4,283.42
3,179.72
2,520.37
2,360.18
2,404.94
Basic Weighted Avg Shares
7
7
11
11
11
11
13
16
16
16
15
15
15
Sales/Revenue/Turnover
8,547
9,003
7,920
8,603
8,728
12,864
68,054
49,296
28,754
13,261
11,369
11,288
13,756
Operating Margin (%)
3.48
-4.8
-18.67
-11.89
-20.93
-1.64
44.59
21.59
-6.15
-104.62
-83.49
-24.69
5.58
Depreciation Expense
253
364
437
470
400
1,593
1,939
2,369
1,944
1,175
1,373
1,347
1,281
Net Income, GAAP
-32
2,597
-1,784
-1,947
-2,708
-1,432
24,159
9,479
-2,673
-16,122
-10,166
-2,540
1,060
Effective Tax Rate (%)
- -
16.02
- -
- -
- -
- -
17.5
14.6
- -
- -
- -
- -
0.74
Profit Margin (%)
-0.37
28.85
-22.52
-22.63
-31.03
-11.13
35.5
19.23
-9.3
-121.57
-89.42
-22.5
7.7
Working Capital
-4,873
3,312
8,533
7,220
478
-2,741
27,934
56,016
38,315
16,777
5,614
3,371
3,509
LT Debt
6,743
8,388
13,280
13,331
10,635
9,073
13,126
15,400
4,541
3,743
4,688
4,017
2,636
Total Equity
1,825
10,253
9,863
7,897
5,481
4,189
39,622
71,592
67,884
49,810
39,260
36,635
37,406
Return on Invested Capital (%)
- -
-2.25
- -
- -
- -
- -
62.57
12.26
- -
- -
- -
- -
0.96
Return on Capital (%)
- -
19.1
- -
- -
- -
- -
64.29
14.75
- -
- -
- -
- -
3.06
Return on Common Equity (%)
- -
43
-17.75
-21.98
-41.83
-31.4
113.22
17.29
-3.86
-27.49
-22.88
-6.7
2.87

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12,017
11,773
12,768
LT Borrowings
3,934
3,747
2,561
LT Finance Leases
84
78
75
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
29,228
53,621
30,375

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
17,932
19,393
18,923
Cash, Cash Equivalents & STI
7,143
7,524
6,851
Accounts Receivable, Net
1,547
1,964
1,198
Inventories
8,609
9,162
10,025
Total Current Liabilities
14,561
15,225
15,413
Payables & Accruals
- -
- -
- -
ST Debt
12,017
11,773
12,768
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
78.89%
4.2%
-6.69%
Free Cash Flow
-116.25%
-291.65%
-65.49%
Net Income, GAAP
-175.25%
40.43%
-75.02%
Sales/Revenue/Turnover
33.64%
-27.62%
-0.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,918
3,162
1,651
3,638
11,369
2025
2,909
2,365
2,784
3,230
11,288
2026
3,880
3,863
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-122
-109
-153
-272.49
-656
2025
-70
-109
-10.53
26.02
-164
2026
38.01
15
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jong-Cheol Kim
Full Time Employees
85
Sector
Health technology
Industry
Medical specialties
Address
Paju-si South Korea
IPO Date
Dec 14, 2015
Website
mek-ics.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
MEKICS Co., Ltd. is a South Korea-based medical device company primarily engaged in the research, development, manufacturing, and distribution of specialized critical care respiratory equipment and patient monitoring systems. Founded in 1998 and headquartered in Paju-si, Gyeonggi-do, South Korea, the company serves intensive care units, emergency rooms, sub-acute care environments, and home healthcare markets across domestic and international territories. The company organizes its offerings into specialized medical device and accessory segments, comprising intensive care mechanical ventilators, including the MV2000 series, MTV1000, and OmniVent models; high-flow nasal cannula (HFNC) oxygen therapy systems, including the HFT500 and HFT700 product lines; transport and emergency resuscitation ventilators; non-invasive positive airway pressure ventilation devices; multi-parameter patient monitors and pulse oximeters for continuous vital sign assessment; and specialized respiratory consumables and accessories, including heated breathing circuits, humidification chambers, patient masks, and nasal cannulas. MEKICS operates an international distribution network spanning Asia-Pacific, Europe, North America, Latin America, and the Middle East through regional distributors, sales subsidiaries, and healthcare partners. In recent developments, MEKICS has advanced its global compliance pathway under European Union Medical Device Regulation (EU MDR) standards and broadened foreign market registrations; introduced next-generation high-flow respiratory care systems equipped with enhanced automated oxygen delivery algorithms; established new commercial distribution and OEM supply agreements to expand market presence across North American and emerging overseas markets; and executed operational workflow enhancements at its Paju manufacturing facilities to scale production capacity for core ventilation platforms and proprietary consumable lines.